Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1

Yue Lu; Alphonsus H. C. Ng; Frances E. Chow; Richard G. Everson; Beth A. Helmink; Michael T. Tetzlaff; Rohit Thakur; Jennifer A. Wargo; Timothy F. Cloughesy; Robert M. Prins; James R. Heath

doi:10.1038/s41467-021-24293-4

Nature Communications (Jun 2021)

Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1

Yue Lu,
Alphonsus H. C. Ng,
Frances E. Chow,
Richard G. Everson,
Beth A. Helmink,
Michael T. Tetzlaff,
Rohit Thakur,
Jennifer A. Wargo,
Timothy F. Cloughesy,
Robert M. Prins,
James R. Heath

Affiliations

Yue Lu: Institute for Systems Biology
Alphonsus H. C. Ng: Institute for Systems Biology
Frances E. Chow: Department of Medical and Molecular Pharmacology, David Geffen School of Medicine, University of California, Los Angeles
Richard G. Everson: Department of Medical and Molecular Pharmacology, David Geffen School of Medicine, University of California, Los Angeles
Beth A. Helmink: Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center
Michael T. Tetzlaff: Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center
Rohit Thakur: Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center
Jennifer A. Wargo: Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center
Timothy F. Cloughesy: Department of Medical and Molecular Pharmacology, David Geffen School of Medicine, University of California, Los Angeles
Robert M. Prins: Department of Medical and Molecular Pharmacology, David Geffen School of Medicine, University of California, Los Angeles
James R. Heath: Institute for Systems Biology

DOI: https://doi.org/10.1038/s41467-021-24293-4
Journal volume & issue: Vol. 12, no. 1
pp. 1 – 13

Abstract

Read online

The response to neoadjuvant immune checkpoint blockade (ICB) in patients with recurrent gliolastoma multiforme (GBM) has been challenging to interpret. Here the authors develop a tumor analysis framework that reveals molecular similarities between GBM and melanoma and unique patterns of immunosuppression in GBM indicating potential co-targets for neoadjuvant ICB.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal